Island Pharmaceuticals Expands Pipeline to Three New Viruses Backed by $780K Grant

Strategic Expansion of Antiviral Portfolio

Island Pharmaceuticals Limited (ASX:ILA) has announced a significant step forward in its antiviral drug development strategy through a new collaboration with the Burnet Institute, a leading Australian infectious disease research organisation. The partnership aims to broaden the therapeutic scope of Island’s two key antiviral candidates, ISLA-101 and Galidesivir, by investigating their efficacy against additional viral threats including measles, chikungunya, and Ross River virus.

These viruses represent pressing global and national health challenges, with no approved antiviral treatments currently available. Measles remains one of the most contagious human viruses worldwide, chikungunya causes millions of infections annually across more than 100 countries, and Ross River virus affects thousands of Australians each year. By targeting these pathogens, Island is positioning its assets within critical public health and biodefence frameworks.

Leveraging Expertise and Existing Data

The collaboration is led by Dr Johanna Fraser, Head of the Arbovirology Working Group at Burnet Institute and co-lead inventor of ISLA-101. Dr Fraser brings deep expertise in mosquito-borne viruses and antiviral drug development, ensuring scientific continuity and domain knowledge. Her recent success in securing a competitive NHMRC grant exceeding $780,000 further strengthens the research effort, providing meaningful funding to advance clinical and translational studies.

Importantly, the program will capitalise on Island’s existing clinical and preclinical datasets, avoiding the need for new molecule acquisitions or substantial capital investment. This approach not only maximises the value of ISLA-101 and Galidesivir but also aligns with government biodefence preparedness and strategic stockpile initiatives, potentially enhancing the assets’ commercial and strategic appeal.

Implications for Island’s Development Pipeline

Island’s CEO, Dr David Foster, emphasised the strategic importance of this collaboration, highlighting how it expands the company’s antiviral portfolio and strengthens its intellectual property position. The initiative dovetails with Island’s broader Phase 2/3 development plans, aiming to deliver broad-spectrum antivirals with clear regulatory pathways and strong partnership potential.

With Galidesivir already boasting a broad spectrum of activity against over 20 RNA viruses, including high-profile pathogens such as Ebola and Marburg, and ISLA-101 showing promise in dengue fever treatment, this expanded research could unlock new commercial opportunities and enhance global health security.

Overall, the collaboration represents a thoughtful, resource-efficient strategy to address unmet medical needs while aligning with national health priorities, positioning Island Pharmaceuticals as a key player in antiviral innovation.